Detachment of non-malignant epithelial cells from the extracellular matrix causes their apoptosis, a phenomenon called anoikis. By contrast, carcinoma cells are anoikis-resistant, and this resistance is thought to be critical for tumor progression. Many oncogenes trigger not only anti-but also pr-apoptotic signals. The proapoptotic events represent an aspect of a phenomenon called oncogenic stress, which acts as a safeguard mechanism blocking tumor initiation. In cells that become malignant, oncogene-induced antiapoptotic signals outbalance the proapoptotic ones. It is now thought that treatments blocking the antiapoptotic events but preserving the proapoptotic signals can be particularly effective in killing tumor cells. Whether or not oncogenes induce any proanoikis signals that can be used for enhancing the efficiency of approaches aimed at triggering anoikis of cancer cells has never been explored. β-Catenin is a major oncoprotein that is often activated in colorectal cancer and promotes tumor progression via mechanisms that are understood only in part. We found here that β-catenin triggers both anti-and proanoikis signals in colon cancer cells. We observed that the antianoikis signals prevail and the cells become anoikis-resistant. We further established that one proanoikis signal in these cells is triggered by β-catenin-induced downregulation of an apoptosis inhibitor tumor necrosis factor receptor 1 (TNFR1) and subsequent reduction of the activity of a transcription factor NF-κB (nuclear factor-κB), a mediator of TNFR1 signaling. We also found that the effect of β-catenin on TNFR1 requires the presence of transcription factor TCF1, a β-catenin effector. We demonstrated that ablation of β-catenin in colon cancer cells triggers their anoikis and that this anoikis is enhanced even further if low TNFR1 or NF-κB activity is artificially preserved in the β-catenin-deprived cells. Thus, inhibition of TNFR1 or NF-κB activity can be expected to enhance the efficiency of approaches aimed at blocking β-catenin-driven anoikis resistance of colon carcinoma cells.
INTRODUCTION
Many normal epithelia are organized in vivo into cellular monolayers, which are attached to the basement membrane (BM), a form of the extracellular matrix (ECM). Detachment of epithelial cells from the ECM causes their apoptosis, 1,2 a phenomenon termed anoikis. 2 Unlike normal epithelia, carcinomas represent three-dimensional disorganized multicellular masses in which cell-ECM contacts are changed significantly. It is known in this regard that cancer cells often secrete BMdegrading enzymes. This allows tumors to invade other tissues. 3 Moreover, at advanced stages aggregates of cancer cell detach from the tumor and give rise to metastases. 4, 5 Even though carcinoma cells are deprived of normal contacts with the BM throughout tumor progression, a significant fraction of these cells are viable. 4, 5 Numerous data indicate that anoikis resistance of malignant cells is essential for carcinoma progression. First, cancer cells can often survive and grow without adhesion to the ECM as colonies in soft agar, and such growth represents a hallmark of the malignant phenotype. 6, 7 Second, we and others found that activation of oncoproteins (e.g. Ras, 1 Src, 8 EGF receptor (EGFR), 9 Akt 10 and β-catenin 11 ) or loss of tumor suppressor genes (e.g. PTEN 12 ) inhibits anoikis of cancer cells. In addition, we and others established that treatments blocking anoikis resistance of such cells suppress their ability to form primary tumors [13] [14] [15] [16] [17] [18] and metastases. 5, 13, 16, 19, 20 Moreover, we found 21 that acquisition of anoikis resistance by non-malignant cells is sufficient for the attainment of in vivo tumorigenicity by such cells. Thus, anoikis resistance of tumor cells is critical for tumor progression 4, 22, 23 and may serve as a novel therapeutic target. However, no effort to exploit this property of tumor cells in the design of cancer therapy has been undertaken to date. This is most likely due to the fact that the mechanisms controlling anoikis resistance of cancer cells are understood only in part.
Given that many oncogenes render cancer cells anoikisresistant, direct targeting of these oncogenes represents one potential approach for blocking such resistance. It is known in this regard that many major oncoproteins, for example, Ras, EGFR, Src, Akt and Bcr-Abl, control apoptosis in a complex manner in that they trigger not only anti-but also proapoptotic signals in cells. 24, 25 The latter signals represent an aspect of a phenomenon called 'oncogenic stress', 26 oncogene-induced activation of antioncogenic pathways causing apoptosis or cell cycle arrest. 26 Oncogenic stress is thought to serve as a safeguard mechanism that blocks tumor growth. 27 In those cells that do become malignant, oncogene-induced antiapoptotic signals outbalance the proapoptotic signals. 24 As a result, cancer cells remain viable.
It was proposed that oncogene-induced proapoptotic signals can be used for killing cancer cells. 24, 28 It was found in this regard that loss of oncogenes or inhibition of their activity in cancer cells can create a situation when proapoptotic signals prevail in these cells for a certain period of time. For example, it was found that ablation of onocoproteins, such as Src, BCR-ABL, or pharmacological inhibition of EGFR activity in tumor cells kills a significant fraction of these cells. To explain the mechanisms of such death, it was proposed that loss of expression or activity of these oncoproteins causes rapid inhibition of oncoprotein-induced survival signals and a much slower blockade of oncoproteindependent death signals. The mechanisms of this process termed 'differential signal decay' 24 remain to be understood but it was proposed that the time window during which the death signals are preserved in oncoprotein-deprived tumor cells is sufficient for irreversible commitment of these cells to death, a phenomenon called 'oncogenic shock'. 24, 28 However, prolonged oncogene loss blocks both life and death signals, and cancer cells that have not died within the indicated time period remain alive. Thus, artificial preservation of oncogene-induced proapoptotic signals could increase efficiency of apoptosis-inducing treatment based on direct inhibition of oncogene expression or activity in cancer cells. Whether or not oncogenes induce proapoptotic signals that can be used for enhancing the efficiency of approaches aimed at triggering anoikis of tumor cells has never been explored.
Oncogenic mutations activating a signaling regulator β-catenin often occur in colorectal and other cancers. 29 In normal cells, β-catenin typically forms a complex with molecules involved in cell-cell contact. 29 Excessive β-catenin is removed from such cells by a complex composed of adenomatous polyposis coli (APC) and other proteins. 29 In carcinomas, β-catenin loss is often suppressed by either loss-of-function mutations of APC or those of β-catenin that render β-catenin stable. 29 Once stabilized, excessive β-catenin moves to the nucleus where it binds and activates transcription factors of the LEF/TCF (lymphoid-enhancing factor/T-cell factor) family, for example, TCF1, 3 and 4. 29 Subsequent changes in the expression of the LEF/TCF target genes are thought to contribute to tumor initiation 29 and metastasis. 30, 31 Therapeutic approaches aimed at the inhibition of β-catenin signaling in cancer cells are presently being developed. 32 We found previously that β-catenin blocks anoikis of colon cancer cells by downregulating a proapoptotic protein DAP kinase-2 (DAPk2). 18 We show here that in addition to triggering the antianoikis signals, β-catenin activates proanoikis events, such as the downregulation of tumor necrosis factor receptor 1 (TNFR1), in these cells. This downregulation is mediated by TCF1. We also observed that β-catenin-induced TNFR1 loss reduces the activity of transcription factor NF-κB (nuclear factor-κB), a mediator of TNFR1 signaling. We demonstrated that β-catenin ablation triggers anoikis of colon cancer cells and that this anoikis is enhanced even further if low TNFR1 or NF-κB activity is artificially preserved in the β-catenin-deprived cells. Thus, TNFR1 or NF-κB antagonists can be expected to enhance the efficiency of approaches aimed at blocking β-catenin-dependent anoikis resistance of colon carcinoma cells. HT-29 (c), SW-480 (d) and HCT-116 (e) were transfected with 100 nM control RNA (cont RNA) or β-catenin-specific siRNA (βcatsiRNA) 2 and 4 and assayed for TNFR1 expression by western blot. Membranes were stripped and reprobed with an anti-β-catenin antibody and then an anti-β-actin antibody, which served as a loading control.
TNFR1 antagonists enhance anoikis of tumor cells

RESULTS
β-catenin downregulates TNFR1 in human colon carcinoma cells
We found previously that β-catenin ablation by RNA interference (RNAi) triggers anoikis of human colon carcinoma cells DLD-1, in which the wild-type β-catenin is activated by the loss-of-function APC mutations. 33 In an effort to further understand the mechanisms by which β-catenin controls anoikis of cancer cells, we found that β-catenin loss causes a significant upregulation of TNFR1 in DLD-1 cells (Figure 1a ). We observed a similar effect in human colon cancer cell lines SKCO-1, HT-29 and SW-480, in which the wild-type β-catenin is thought to be activated by the loss-offunction APC mutations [34] [35] [36] and in human colon cancer cells HCT-116, which harbor the wild-type APC and a mutant β-catenin allele coding for abnormally stable β-catenin 33 (Figures 1b-e ). Thus, β-catenin downregulates TNFR1 in human colon carcinoma cells. As, depending on the circumstances, TNFR1 can trigger cell survival or death, 37 we decided to explore its role in the control of β-catenin-dependent anoikis of colon cancer cells.
Enforced TNFR1 downregulation enhances anoikis of colon cancer cells triggered by β-catenin loss TNFR1 can be activated by its ligand TNF-α. 37 It is also well known that increased TNFR1 expression can cause ligand-independent TNFR1 activation. 38, 39 Furthermore, it was proposed that TNFR1 can self-aggregate and become active spontaneously (in the absence of TNF-α), and this activation can be blocked by a protein called SODD. 40 TNF-α is produced by cells as a membrane-bound protein, which can be cleaved to give rise to a soluble form. 41 Both forms of TNF-α are biologically active. 41 We found that DLD-1 and SKCO-1 cells produce neither soluble nor membrane-bound TNF-α before or after β-catenin ablation ( Figure 2 ).
As increased TNFR1 expression can cause ligand-independent TNFR1 activation, 38, 39 we reasoned that TNFR1 could be activated (and thus control anoikis) in the absence of TNF-α when TNFR1 expression is increased after β-catenin loss by cancer cells. Indeed, we found that β-catenin-directed RNAi induces some degree of apoptosis of detached SKCO-1 cells and that TNFR1 ablation by RNAi enhances this death even further (Figures 3a-c). By contrast, TNFR1-and β-catenin-specific small interfering RNAs (siRNAs) did not cooperate with each other in killing the attached cells ( Figures 3d and e ). We also observed that TNFR1-and β-cateninspecific siRNAs cooperate with each other in killing detached colon carcinoma cells HT-29 (Figures 3f-h). Furthermore, we found that β-cateninand TNFR1-directed siRNAs cooperate with each other in triggering anoikis of DLD-1 cells ( Figure 4 ). In this case, when β-catenin alone was ablated, anoikis of DLD-1 cells was not observed until they were detached from the ECM for 72 h (Figure 4c ). However, when downregulation of both β-catenin and TNFR1 was enforced, the cells underwent apoptosis as early as at 24 h after detachment (Figures 4d and e ). Thus, antagonists of β-catenin and those of TNFR1 cooperate with each other in killing detached colon cancer cells.
Our finding that TNFR1 loss enhances anoikis of β-catenindeprived cells indicates that TNFR1 acts as anoikis inhibitor in this context. Hence, β-catenin induces both anti-(e.g. DAPk2 loss as we published 18 ) and proapoptotic (e.g. TNFR1 loss) events in these cells. The antianoikis signals outbalance the proanoikis ones, and the cells become anoikis-resistant. Once β-catenin is ablated, the antianoikis signals are blocked, and the cells undergo some degree of anoikis. However, β-catenin loss also upregulates TNFR1, and this upregulation causes ligand-independent TNFR1 activation. TNFR1-induced survival signals reduce the degree of anoikis of β-catenin-deprived cells. Hence, when TNFR1 expression is suppressed in these cells, their anoikis is increased even further (see Figure 10 for our model of these events).
Transcription factor TCF1 is required for maintaining low TNFR1 levels in colon cancer cells In an effort to understand the mechanisms by which β-catenin downregulates TNFR1 in colon cancer cells, we first established that β-catenin ablation in SKCO-1 cells causes TNFR1 mRNA upregulation ( Figure 5a ). We further tested which of the TCF transcription factors mediating β-catenin signaling 29 is required for TNFR1 downregulation in cancer cells. We found that ablation of transcription factor TCF1 but not that of TCF4 by RNAi in SKCO-1 cells upregulates TNFR1 (Figures 5b and c) . These data are consistent with a scenario, according to which β-catenin-induced TNFR1 downregulation in cancer cells is TCF1 dependent. The fact that TCF1 triggers a proapoptotic signal, such as that driven by TNFR1 loss, in cancer cells is consistent with observations that TCF1 is a tumor suppressor in mice (TCF1 gene loss in mice promotes the formation of intestinal adenomas 42 ).
β-Catenin LEF/TCF transcription factors can directly block gene expression by binding the TCF recognition sites within respective promoters. 43, 44 Thus, TCF1 could, in principle, downregulate TNFR1 directly, by binding its promoter. Alternatively, TCF1 could downregulate TNFR1 indirectly, by altering the levels of known and/or unknown regulators of TNFR1 expression. To distinguish between these possibilities, we used chromatin immunoprecipitation to establish whether β-catenin and TCF1 can bind chromosomal regions upstream of the TNFR1 transcription start site. To validate this technique in our model system, we verified that this assay detects β-catenin and TCF1 binding to the region located upstream of the transcription start site of Axin 2 gene, a known β-catenin/TCF target, 45 in SKCO-1 cells (Figure 5d ). The chromosomal region that controls TNFR1 gene expression is located within 800 bp upstream of the transcription start site (position +1 of the TNFR1 gene). 46 We found that none of the DNA fragments within the chromosomal region starting at position +1 and extending as far as position − 1900 can bind β-catenin or TCF1 in SKCO-1 cells (Figure 5d ). Thus, our data are consistent with a scenario, according to which β-catenin and TCF1 downregulate TNFR1 in colon cancer cells indirectly, for example, by altering cellular levels of yet unidentified regulators of TNFR1 expression. TNFR1 does not regulate the activity of Mek and p38 MAP kinases in β-catenin-deprived colon cancer cells We further investigated the mechanisms by which TNFR1 contributes to the control of anoikis of colon cancer cells. TNFR1 can trigger signaling events that are capable of blocking apoptosis, including the activation of a protein kinases Mek and p38 mitogen-activated protein kinase (MAPK). 47 To test whether Mek and p38 are involved in the effect of TNFR1 on colon cancer cells, we assayed Mek target protein kinases Erk 1 and 2 and p38 MAPK for phosphorylation (a method often used for measuring Mek 14 and p38 MAPK 48 activity, respectively). We found that β-catenin ablation by RNAi increases Erk 1 and 2 phosphorylation in SKCO-1 cells. However, this increase was not TNFR1-dependent ( Figure 6a ). We further found that TNFR1-specific siRNAs did not alter the level of p38 MAPK phosphorylation in β-catenin-deficient SKCO-1 cells (Figure 6b ). Thus, Mek or p38 MAPK are unlikely involved in the regulation of anoikis by TNFR1 in colon cancer cells.
Transcription factor NF-κB mediates the effect of TNFR1 on anoikis The prosurvival effect of TNFR1 is often mediated by transcription factor NF-κB. 37 In the absence of activating stimuli, NF-κB is retained in the cytoplasm in an inactive state by the IκB inhibitor. 37 When activated, TNFR1 induces protein kinase IKKβ, which phosphorylates and thus targets IκB for proteasomal degradation. This allows NF-κB to promote transcription of genes coding for antiapoptotic proteins. 37 β-Catenin can also activate NF-κB. 49, 50 This activation occurs directly via the formation of a complex composed of NF-κB, β-catenin and LEF/TCF transcription factors. 50 We therefore hypothesized that β-catenin loss triggers proanoikis signals in cancer cells and this causes some degree of their anoikis. We speculated that β-catenin loss also reduces NF-κB activity in such cells to a certain extent (such reduction could contribute to anoikis) and that TNFR1 ablation inactivates NF-κB even further. This would be expected to increase their anoikis further. Indeed, we found that β-catenin ablation in SKCO-1 cells causes some degree of NF-κB inactivation (measured by an NF-κB reporter assay 51 ) and that TNFR1-directed RNAi suppressed NF-κB activity in the β-catenin-deprived cells even further (Figure 7) .
In an effort to demonstrate the involvement of NF-κBdependent signaling in the antianoikis effect of TNFR1 by a complimentary approach, we used a gene expression microarray analysis and found (Table 1a ) that TNFR1 ablation in β-catenindeprived SKCO-1 cells results in the downregulation of multiple mRNAs coding for established apoptosis inhibitors, whose expression is known to be stimulated by NF-κB, such as PDGFβ 52, 53 ErbB2, 54, 55 Galectin 3, 57,56 S100A4, 59,58 Ass1 61,60 and PKAα. 62, 63 By contrast, we found that the expression of a number of mRNAs coding for those apoptosis regulators whose expression is not known to be NF-κB-dependent (Table 1a) , such as components of cellular apoptotic machinery or survivalpromoting protein kinases, was not altered by TNFR1 loss in any consistent manner. All changes in the expression of mRNAs of apoptosis inhibitors whose expression is known to be NF-κBdependent were confirmed by quantitative PCR (qPCR) (Table 1b) . Thus, TNFR1 loss in β-catenin-deprived cells causes NF-κB inactivation and the downregulation of multiple apoptosis inhibitors that represent known NF-κB effectors. Hence, if NF-κB contributes to the regulation of anoikis of such cells (which as shown below is the case), targeting NF-κB itself, rather than its multiple effectors, would likely represent a feasible approach for killing detached β-catenin-deprived cancer cells.
To test directly whether NF-κB indeed contributes to the regulation of anoikis of colon cancer cells by β-catenin, we infected SKCO-1 cells (before and after β-catenin ablation) with a recombinant adenovirus (Ad5IκB) carrying a mutant form of NF-κB inhibitor IκBα that is resistant to proteasomal degradation. 64 Of note, in the course of these studies we found that β-catenin ablation downregulates the endogenous IκBα protein in cancer cells (Figure 8a , compare lanes 1 and 3 from left) without altering IκBα mRNA levels (Figure 8b ). This downregulation could be reversed by TNFR1 ablation (Figure 8c ). Thus, it seems likely that β-catenin loss upregulates TNFR1 and TNFR1 (as expected 37 ) triggers IκB protein degradation.
Our findings are consistent with observations that β-catenin and LEF/TCF transcription factors activate NF-κB directly, by forming a complex with this protein in the nucleus. 50 It is conceivable that β-catenin loss disrupts the indicated complex and inactivates NF-κB to some extent. However, as β-catenin ablation also causes TNFR1 upregulation, it seems likely that TNFR1 triggers IκBα degradation and this increases nuclear NF-κB levels. Presumably, the increased flow of NF-κB to the nucleus precludes NF-κB inactivation (induced by β-catenin loss) below a certain level. Therefore, it seems likely that the use TNFR1 antagonists or that of the dominant-negative IκBα causes the increase of IκBα concentration in the cytoplasm of the β-catenindeprived cells and subsequent decrease in the amount of NF-κB in the nucleus. As a result, NF-κB is inactivated in these cells even further.
We also observed that as expression of endogenous IκBα is reduced in SKCO-1 cells after β-catenin loss, expression of the exogenous virus-encoded IκB is increased (Figure 8a, compare  lanes 2 and 4 from left) . A similar result was achieved when the cells were first infected with Ad5IκB and then deprived of β-catenin (not shown). One possible explanation of these findings is that a regulatory mechanism exists that prevents the total amount of (endogenous and exogenous) IκBα from exceeding a certain level in cancer cells. Constant IκBα levels could be supported in cancer cells owing to the fact that the exogenous, non-degradable, IκBα displaces the degradable endogenous IκBα (whose turnover is presumably faster) from such cells. It is also worth noting that IκB expression can be controlled at the level of its mRNA stability. 65, 66 Thus, it is possible that the indicated mechanism prevents the expression of the total IκBα-encoding mRNA from exceeding a certain level in cancer cells. Regardless of its exact nature, the existence of the indicated mechanism was beneficial for our study: it ensured that total IκBα amount (endogenous and exogenous) in Ad5IκB-infected cells remained relatively constant before and after β-catenin ablation (Figure 8a , compare lanes 2 and 4 from left). This allowed us to compare directly IκB-dependent anoikis of these cells before and after β-catenin loss.
We observed that in case of the control virus-infected SKCO-1 cells, β-catenin loss causes some degree of anoikis. When β-catenin-deficient cells were infected with the Ad5IκB virus, their anoikis was increased further (Figure 8d ).
In an effort to confirm these data by a complementary approach that does not rely on the introduction of exogenous IκB into cancer cells, we found that small-molecule antagonists of NF-κB (CAPE; Natarajan et al. 67 ) and β-catenin (FH535; Handeli and Simon 68 ) cooperated with each other in triggering anoikis of colon cancer cells (Figures 9a-d) and blocking their growth without adhesion to the ECM as colonies in soft agar (Figure 9e ) (we often use the latter assay for measuring the long-term survival and growth of cancer cells without adhesion to the ECM). 14, 15, 18 A similar cooperation in blocking such growth was observed between β-catenin antagonist FH535 and JSH-23, 69 another NF-κB antagonist that is structurally unrelated to CAPE (Figure 9f ).
We conclude that β-catenin induces both anti-(e.g. DAPK2 downregulation 8 ) and proanoikis (TNFR1 loss) events in colon cancer cells. The antianoikis signals outbalance the proanoikis ones, and the cells become anoikis-resistant. β-Catenin antagonists trigger proapoptotic signals in cancer cells and this causes Abbreviations: βcatsiRNA, β-catenin-specific siRNA; cont RNA, control RNA; NF-κB, nuclear factor-κB; siRNA, small interfering RNA; TNFR1, tumor necrosis factor receptor 1; TNFR1siRNA, TNFR1-specific siRNA. SKCO-1 cells were transfected (+) or not transfected ( − ) with 50 nM cont RNA together with βcatsiRNA2 or 50 nM βcatsiRNA2 together with 50 nM TNFR1siRNA5 or 50 nM βcatsiRNA2 together with 50 nM TNFR1siRNA6, and changes in the mRNA expression in the β-catenin-deprived cells caused by TNFR1 loss were examined by use of a gene expression microarray. Levels of each mRNA in cells transfected with cont RNA and βcatsiRNA2 were designated as 100%. TNFR1 mRNA levels are shown as a positive control. 'NF-κB target mRNAs of apoptosis inhibitors' are the mRNAs coding for established apoptosis inhibitors whose expression is known to be NF-κB-dependent. Changes in the levels of mRNAs of apoptosis regulators that are not known to be controlled by NF-κB are shown as negative controls. NCBI reference sequence numbers for the genes shown in the figure are as follows: PDGFβ, NM_002608; galectin 3, NM_001177388; S100A4, NM_002961; Ass1, NM_000050; ErbB2, NM_001005862; PKAα, NM_002730; caspase-2, NM_032982; caspase-6, NM_001226; Bid, NM_197966; Akt1, NM_005163; Raf1, NM_002880. Samples were derived from two transfections that were performed independently of each other (on different days) (Experiments 1 and 2). Table 1b . TNFR1 loss in β-catenin-deprived human colon carcinoma cells downregulates mRNAs coding for antiapoptotic proteins, whose expression is known to be NF-κB-dependent: qPCR (validation of the microarray data) mRNAs of apoptosis inhibitors whose expression is NF-κB-dependent βcatsiRNA2 PDGFβ  100  44  3  50  1  Galectin 3  100  59  2  60  2  S100A4  100  65  3  66  6  Ass1  100  46  1  49  4  ErbB2  100  76  3  67  2  PKAα  100  51  2  50  3 Abbreviations: βcatsiRNA, β-catenin-specific siRNA; cont RNA, control RNA; NF-κB, nuclear factor-κB; qPCR, quantitative PCR; siRNA, small interfering RNA; TNFR1, tumor necrosis factor receptor 1; TNFR1siRNA, TNFR1specific siRNA. SKCO-1 cells were transfected as in (a) and changes in the mRNA expression in the β-catenin-deprived cells caused by TNFR1 loss were examined by qPCR. The observed TNFR1 mRNA levels were normalized by the levels of 18S rRNA, which were also determined by qPCR. The resulting levels of each mRNA in cells transfected with cont RNA and βcatsiRNA2 were designated as 100%. The numbers represent the average of the triplicates. S.d. is indicated in each case. All differences between control and experimental samples were statistically significant (Pvalue was o 0.05).
some degree of their anoikis. In addition, these antagonists partially suppress NF-κB activity in such cells (possibly by disrupting the complex between β-catenin and NF-κB). However, NF-κB activity cannot drop below a certain level as β-catenin loss upregulates TNFR1, which counters NF-κB inhibition by triggering signals aimed at NF-κB activation. Thus, when NF-κB activity is further blocked in such cells by TNFR1 or NF-κB antagonists, their anoikis is enhanced even further. Our model of the regulation of anoikis of colon cancer cells by β-catenin and TNFR1 is shown in Figure 10 .
DISCUSSION
We found here that β-catenin and TNFR1 antagonists cooperate with each other in triggering colon cancer anoikis. The relevance of our data to tumor biology stems from numerous observations indicating that anoikis resistance of malignant cells is critical for solid tumor progression. 4, 22, 23 As oncogenes render cancer cells anoikis-resistant, direct targeting of oncogenes represents one potential approach for overcoming this resistance. Indeed, antagonists of oncoproteins, such as EGFR and ErbB2, are presently used for cancer treatment. 70, 71 However, clinical efficacy of these agents is limited. 70, 71 One factor that likely reduces such efficacy is that oncogenes activate not only anti-but also proapoptotic signals in cells. 24, 25 Hence, inhibition of oncogene activity can induce both pro-and antiapoptotic events in such cells. It is conceivable that the antiapoptotic signals counter the proapoptotic ones in respective cells and prevent at least some cells from dying. Thus, the efficacy of oncogene antagonists can be expected to be increased if the antiapoptotic signals triggered by such antagonists are artificially suppressed.
β-catenin oncoprotein has a critical role in colorectal cancer. We found previously that β-catenin renders colon carcinoma cells anoikis-resistant. 18 We show here that in addition to triggering the antianoikis events, β-catenin induces the proanoikis signals, such as TNFR1 downregulation and subsequent reduction of NF-κB activity, in tumor cells. We demonstrated that β-catenin ablation in these cells triggers a certain degree of their anoikis. We established that if TNFR1 or NF-κB activity is blocked in tumor cells, the degree of their anoikis induced by β-catenin ablation is increased significantly. Thus, based on our results, it can be expected that the efficacy of β-catenin-directed approaches aimed at triggering anoikis of cancer cells will be increased by TNFR1 or NF-κB antagonists. The fact that β-catenin and TNFR1 antagonists do not cooperate with each other in killing cells that are attached to the ECM suggests that yet unidentified detachment-induced proapoptotic signals sensitize the cells to those triggered by the indicated antagonists. Our data that TNFR1 is downregulated by β-catenin, an oncoprotein that is often activated in colon cancer, 33 are consistent with observations that TNFR1 expression is reduced in a significant fraction of such cancers. 72 Our data that TNFR1induced NF-κB activation can increase the survival of colon cancer cells that are detached from the ECM are consistent with the fact that NF-κB is an established mediator of TNFR1 antiapoptotic signaling. 37 Furthermore, we published that NF-κB activation can block anoikis of non-malignant intestinal epithelial cells. 51, 73 Our data indicate that β-catenin-induced TNFR1 downregulation in colon cancer cells is mediated by transcription factor TCF1. As we found that TNFR1 loss triggers a proanoikis signal in these cells, it appears that TCF1 can induce proapoptotic (i.e. antioncogenic) events in such cells. The notion that TCF1 can be antioncogenic is consistent with observations that TCF1 gene loss in mice promotes intestinal adenomas, 42 that is, TCF1 is a tumor suppressor. As anoikis resistance of cancer cells is thought to be required not only for tumor invasion and metastasis 5, 13, 16, 19, 20 but also for the formation of primary tumors, [13] [14] [15] [16] [17] [18] it is possible that TCF1deficient mouse intestinal epithelial cells acquire the ability to form adenomas, at least in part, due to their ability to survive without adhesion to the BM.
Our data are consistent with a model, according to which β-catenin triggers both pro-and antioncogenic events, the latter ones being mediated by TCF1-induced TNFR1 downregulation. In those cells that do become malignant, the pro-oncogenic signals prevail. However, TCF1/TNFR1/NF-κB-dependent proanoikis signals still seem to be present in these cells, and the reversal of these signals (which triggers respective survival signals) induced by β-catenin loss reduces anoikis of such cells. Thus, artificial preservation of low TNFR1 or NF-κB activity can be expected to enhance anoikis of colon cancer cells induced by β-catenin antagonists.
Substantial effort is now being made to generate pharmacological β-catenin, 32 TNFR1 74 and NF-κB inhibitors 75 for therapeutic purposes. Our data indicate that small-molecule β-catenin and NF-κB antagonists cooperate with each other in triggering anoikis of colon cancer cells. Thus, treatment based on combining β-catenin antagonists with those of TNFR1 or of NF-κB represents a potential novel approach for colon cancer therapy.
MATERIALS AND METHODS
Cell culture Cells were cultured as described. 14 For suspension cultures, cells were plated above a layer of 1% sea plaque agarose polymerized in Dulbecco's modified Eagle's medium.
Western blot
This assay was performed as described. 14 
RNA interference
RNAi was performed as described. 76 In β-catenin-directed RNAi experiments, 5 × 10 5 cells were transfected with 100 nM of each RNA. In case of simultaneous ablation of β-catenin and TNFR1, total RNA concentration in each transfection reaction was 100 nM (50 nM each RNA). See Supplementary Materials and methods for RNA sequences.
Detecting soluble TNF-α TNF-α ELISA Kit (R&D Systems, Inc., Minneapolis, MN, USA) was used to detect TNF-α according to the manufacturer's instructions.
Adenoviral infection
Replication-defective adenovirus lacking segments of the E1 and E3 regions encoding mutant IκBα was provided by Dr C Jobin. Control adenovirus lacking segments of the E1 and E3 regions not coding for any transgene was provided by Dr J Wang. See Supplementary Materials and methods for details. Figure 10 . Schematic representation of the mechanisms by which antagonists of β-catenin and those of TNFR1 enhance anoikis of colon cancer cells. (a) β-catenin triggers antiapoptotic events (e.g. downregulation of DAPk2) that we published, 18 and proapoptotic events, such as TNFR1 downregulation, in colon cancer cells. The antianoikis signals outbalance the proanoikis signals and the cells become anoikis-resistant. (b) β-catenin antagonists suppress β-catenin-induced survival signals but at the same time trigger TNFR1 upregulation, which activates antiapoptotic events in detached cells. Ultimately, proapoptotic signals outbalance the antiapoptotic ones, and the resulting death signal induces some degree of anoikis of cancer cells. (c) TNFR1 antagonists block TNFR1-dependent survival signals in the cells exposed to β-catenin antagonists. As result, proapoptotic signal in detached cells is increased compared with the situation described in (b) and anoikis of cancer cells is enhanced even further.
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